Deutsche Bank
ELDN icon

Deutsche Bank’s Eledon Pharmaceuticals ELDN Stock Holding History

Deutsche Bank’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$302K Sell
76,643
-12,707
-14% -$46.2K ﹤0.01% 3030
2026
Q1 		$275K Buy
+89,350
New +$210K ﹤0.01% 2863
2025
Q4 		– Sell
-64,110
Closed -$166K – 3651
2025
Q3 		$166K Buy
+64,110
New +$187K ﹤0.01% 3145
2020
Q1 		– Sell
-226
Closed -$2K – 4454
2019
Q4 		$2K Sell
226
-428
-65% -$4.53K ﹤0.01% 4822
2019
Q3 		$7K Sell
654
-1,593
-71% -$22.9K ﹤0.01% 4583
2019
Q2 		$40K Buy
2,247
+1,228
+121% +$53.7K ﹤0.01% 4599
2019
Q1 		$73K Sell
1,019
-1,806
-64% -$120K ﹤0.01% 4427
2018
Q4 		$81K Sell
2,825
-1,225
-30% -$78.1K ﹤0.01% 4299
2018
Q3 		$341K Buy
4,050
+1,611
+66% +$164K ﹤0.01% 3974
2018
Q2 		$307K Buy
2,439
+2,242
+1,138% +$232K ﹤0.01% 4092
2018
Q1 		$17K Buy
+197
New +$14.5K ﹤0.01% 5033
2017
Q4 		– Sell
-18
Closed -$1.36K – 5027
2017
Q3 		$1K Sell
18
-164
-90% -$13.6K ﹤0.01% 4820
2017
Q2 		$18K Buy
182
+150
+469% +$15.3K ﹤0.01% 4578
2017
Q1 		$3K Buy
32
+2
+7% +$294 ﹤0.01% 4747
2016
Q4 		$4K Buy
30
+8
+36% +$1.53K ﹤0.01% 4767
2016
Q3 		$5K Sell
22
-273
-93% -$99.9K ﹤0.01% 4751
2016
Q2 		$262K Sell
295
-1
-0.3% -$1.1K ﹤0.01% 3628
2016
Q1 		$267K Buy
296
+63
+27% +$61.8K ﹤0.01% 3520
2015
Q4 		$328K Buy
233
+1
+0.4% +$1.74K ﹤0.01% 3473
2015
Q3 		$389K Sell
232
-65
-22% -$134K ﹤0.01% 3500
2015
Q2 		$639K Buy
297
+18
+6% +$34.8K ﹤0.01% 3255
2015
Q1 		$510K Sell
279
-301
-52% -$664K ﹤0.01% 3282
2014
Q4 		$1.38M Buy
580
+279
+93% +$662K ﹤0.01% 2968
2014
Q3 		$738K Buy
+301
New +$856K ﹤0.01% 3224

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CCM
Catalio Capital Management New York $532M AUM 171.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ZP
Zimmer Partners New York $4.34B AUM 22.78% 1-Year Est. Return

Deutsche Bank's ELDN Position: Q2 2026 in Review

Deutsche Bank reduced its Eledon Pharmaceuticals (ELDN) stake by 14% in Q2 2026, selling an estimated $46.2K and leaving 76,643 shares worth $302K. The position accounts for ﹤0.01% of the portfolio, ranked #3030.

Deutsche Bank first reported a position in ELDN in Q3 2014 and has held it in 24 quarters since. The position peaked at $1.38M in Q4 2014. 161 funds tracked by Wall St. Rank hold ELDN as of Q2 2026.

  • Deutsche Bank held 76,643 shares of Eledon Pharmaceuticals worth $302K as of Q2 2026.
  • Deutsche Bank sold 12,707 Eledon Pharmaceuticals shares in Q2 2026, an estimated $46.2K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #3030 holding.
  • Deutsche Bank first reported a position in Eledon Pharmaceuticals in Q3 2014 and has held it in 24 quarters since.
  • Deutsche Bank's Eledon Pharmaceuticals position peaked at $1.38M in Q4 2014.
  • 161 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.